Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves. DOGE Stimulus Checks ...

Jefferies lowered the firm’s price target on Vertex (VERX) to $48 from $62 and keeps a Buy rating on the shares. The company’s results beat on ...

In a report released today, Patrick Walravens from JMP Securities maintained a Buy rating on Vertex (VERX – Research Report), with a price ...

Vertex Minerals’ (ASX:VTX) share price fell 3.6% in lunchtime trades to 26cps, even as the company prepares for its first ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

KING OF PRUSSIA, Pa. — KING OF PRUSSIA, Pa. — Vertex, Inc. (VERX) on Thursday reported a loss of $67.8 million in its fourth quarter. On a per-share basis, the King Of Prussia, Pennsylvania-based ...

Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsJoe Crivelli – Vice President of ...

Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today announced the ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited “changing priorities.” ...

Arc’teryx has introduced four new technical models to its footwear roster: Norvan LD 4, Vertex Speed, Norvan Nivalis, Konseal ...